Can a PARP Inhibitor Plus Immunotherapy Improve Recurrent Ovarian Cancer Outcomes?

A phase I/II trial tested the combination of niraparib and pembrolizumab in patients with recurrent ovarian carcinoma.

Source: CancerNetwork - June 25, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news